INVESTMENT

INVESTMENT

Our generation is transforming into a smart-health generation, where the ecosystem demands more cost-effective solutions and higher quality healthcare services. We welcome medtech companies who are positioned to drive the future of health and meet changing market demands. 
Our investments are currently not specified towards any particular healthcare niche. We invest in both AI solutions and medical devices and our current favourite themes are solutions which:


· Provide affordability and effectiveness for emerging markets ·
· Drastically improve the efficiency of current clinical flows ·

· Provide an innovative therapeutic solution for treatment ·


Please note that we do not currently invest in biomedical sciences or pharmaceutical drug discoveries start-ups. 

TRANSFORMING INTO

A SMART-HEALTH GENERATION

FOCUS SECTORS

 

IMPACT

WE WISH OUR INVESTMENT CAN

MAKE A DIFFERENCE AND CREATE POSITIVE IMPACT

Impact is our most important angle when assessing deal flows.

Currently, we measure impacts in the following 3 areas:

01.

01.

The number of patients by whom our portfolio companies benefited post technology commercialization.

02.

02.

Potential dollar-saving to the healthcare system once such economic values become measurable.

03.

03.

The number of people received healthcare access that was not available to them before due to a lack of suppliers or affordability. 

 
 
PORTFOLIO

We currently cover more than ten different sectors across the world. If you want to know more about our portfolio companies, please send an email to us at enquiry@purelandventure.com

STRATEGY

THE FOCUS AREAS AND QUALITIES WE CARE

FOUNDERS & TEAM

IMPACT & CHANGE

SCALABILITY

GOVERNANCE

PROFITS

The Number of People's Lives which technology can change is one thing we constantly have in the forefront of our minds.

We look for companies that bring new solutions to traditional problems in prevention, treatment and medical efficiency, including software and hardware technologies for diagnostic, screening, rehabilitation, biomaterials and workflow improvement. Most importantly, technologies which can have a positive impact and bring maximum value to society are most important to us.

A Product-Market fit is achieved when you can scale in one breath.

Medtech companies often face a heavy research and development burden at the early to mid-stage of the funding cycle and cannot commercialise until a later phase. As a result, there is a preference for companies who truly understand their target markets and know their products are in demand before regulatory approval. 


We do not like companies who rush into product development before taking time to understand what customers truly value. Finally, our fund understands that companies sometimes need to target markets outside of their home markets. Global mindset and ambition are both welcome, but it is requested that the company truly understands how to navigate different markets which are not familiar to them. 

Good Management and Financial Control​ are what we value.

We understand that medtech start-ups generally don’t have the knowledge or resources to build them until Series A. Therefore, our fund will be there to help them, as they are a part of us.

Unique Cycle of Med-Tech companies is what we understand.

Particularly for hardware companies, it can take 2-4 years of continual spending, and this requires investors to have long-term insight and patience. We believe that a long-term approach can help start-ups to go further and avoid unnecessary exit stress for the founders. However, our fund will also keep an eye on businesses which make profits and desire to achieve greatness.

People are the most crucial part of a successful company.

Founders play the most essential roles both in day-to-day operations and long-term company growth. Through our experience, we believe companies can only survive tough situations when founders can predict and face challenges. For example, if a founder can analyse all possible situations of potential failure and has a combat strategy for each, all that remains for him or her is success. 

Backing founders who have a vision and are passionate about making a difference, compared to those who only chase financial returns is important to us. Therefore, looking for founders with the crucial attributes of integrity, intelligence and energy is what our fund does, with integrity being our top priority. 

DEBT OR EQUITY

We lead or participate both Equity Round and Convertible Note Round.

 
  • LinkedIn
CONTACT INFORMATION

Tel: (65) 6816 0278

Fax: (65) 6816 0282

E-mail: enquiry@purelandventure.com

OUR ADDRESS

Singapore Head Office: 1 Sims Lane #04-11 Singapore 387355

Singapore Joint Office: 362 Upper Paya Lebar Road , #04-10, Da Jin Factory, Singapore (534963)

© 2019 by Pureland Group